Alle verbonden artikelen

Impact of lenalidomide maintenance on the immune environment of multiple myeloma patients with low tumor burden after autologous stem cell transplantation.

Auteurs : Fostier K, Caers J, Meuleman N, Broos K, Corthals J, Thielemans K, Schots R, De Keersmaecker B
Jaar : 2018
Journal : Oncotarget
Volume : 9
Pagina's : 20476-20489

Long-term follow-up of 2 patients treated with 90Y-rituximab radioimmunotherapy for relapse of nodular lymphocyte-predominant Hodgkin lymphoma.

Auteurs : Golstein SC, Muylle K, Vercruyssen M, Spilleboudt C, de Wind A, Bron D
Jaar : 2018
Journal : Eur J Haematol
Volume : 101
Pagina's : 415-417

Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis.

Auteurs : Bidard FC, Michiels S, Riethdorf S, Mueller V, Esserman LJ, Lucci A, Naume B, Horiguchi J, Gisbert-Criado R, Sleijfer S, Toi M, Garcia-Saenz JA, Hartkopf A, Generali D, Rothé F, Smerage J, Muinelo-Romay L, Stebbing J, Viens P, Magbanua MJM, Hall CS, Engebraaten O, Takata D, Vidal-Martínez J, Onstenk W, Fujisawa N, Diaz-Rubio E, Taran FA, Cappelletti MR, Ignatiadis M, Proudhon C, Wolf DM, Bauldry JB, Borgen E, Nagaoka R, Carañana V, Kraan J, Maestro M, Brucker SY, Weber K, Reyal F, Amara D, Karhade MG, Mathiesen RR, Tokiniwa H, Llombart-Cussac A, Meddis A, Blanche P, dHollander K, Pantel K
Jaar : 2018
Journal : J Natl Cancer Inst
Volume : 110(6)
Pagina's : 560-567

Dual JAK1 and STAT3 mutations in a breast implant-associated anaplastic large cell lymphoma.

Auteurs : Letourneau A, Maerevoet M, Milowich D, de Wind R, Bisig B, Missiaglia E, de Leval L
Jaar : 2018
Journal : Virchows Arch
Volume : 473
Pagina's : 505-511

Advanced Glycation End-Products-, C-Type Lectin- and Cysteinyl/ Leukotriene-Receptors in Distinct Mesenchymal Stromal Cell Populations: Differential Transcriptional Profiles in Response to Inflammation.

Auteurs : Najar M, Fayyad-Kazan M, Raicevic G, Fayyad-Kazan H, Meuleman N, Bron D, Lagneaux L
Jaar : 2018
Journal : Cell J
Volume : 20
Pagina's : 250-258

Multidisciplinary development of the Geriatric Core Dataset for clinical research in older patients with cancer: A French initiative with international survey.

Auteurs : Paillaud E, Soubeyran P, Caillet P, Cudennec T, Brain E, Terret C, Etchepare F, Mourey L, Aparicio T, Pamoukdjian F, Audisio RA, Rostoft S, Hurria A, Bellera C, Mathoulin-Pélissier S, + collaborators (among others :, Bron D
Jaar : 2018
Journal : Eur J Cancer
Volume : 103
Pagina's : 61-68

Tumor PIK3CA Genotype and Prognosis in Early-Stage Breast Cancer: A Pooled Analysis of Individual Patient Data.

Auteurs : Zardavas D, Te Marvelde L, Milne RL, Fumagalli D, Fountzilas G, Kotoula V, Razis E, Papaxoinis G, Joensuu H, Moynahan ME, Hennessy BT, Bieche I, Saal LH, Stal O, Iacopetta B, Jensen JD, OToole S, Lopez-Knowles E, Barbaraeschi M, Noguchi S, Azim HA Jr, Lerma E, Bachelot T, Wang Q, Perez-Tenorio G, Can de Velde CJH, Rea DW, Sabine V, Bartlett JMS, Sotiriou C, Michiels S, Loi S
Jaar : 2018
Journal : J Clin Oncol
Volume : 36(10)
Pagina's : 981-990

Central nervous system relapse in patients over 80 years with diffuse large B-cell lymphoma: an analysis of two LYSA studies.

Auteurs : Cabannes-Hamy A, Peyrade F, Jardin F, Emile JF, Delwail V, Mounier N, Haioun C, Perrot A, Fitoussi O, Lara D, Delarue R, André M, Offner F, Ghesquières H, Pascal L, Soussain C, Lazarovici J, Schiano JM, Gaulard P, Tilly H, Thieblemont C, + collaborators (among others :, Maerevoet M
Jaar : 2018
Journal : Cancer Med
Volume : 7
Pagina's : 539-548

Immunological impact of Wharton's Jelly mesenchymal stromal cells and natural killer cell co-culture.

Auteurs : Najar M, Fayyad-Kazan M, Meuleman N, Bron D, Fayyad-Kazan H, Lagneaux L
Jaar : 2018
Journal : Mol Cell Biochem
Volume : 447(1-2)
Pagina's : 111-124

Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma.

Auteurs : Morschhauser F, Fowler NH, Feugier P, Bouabdallah R, Tilly H, Palomba ML, Fruchart C, Libby EN, Casasnovas RO, Flinn IW, Haioun C, Maisonneuve H, Ysebaert L, Bartlett NL, Bouabdallah K, Brice P, Ribrag V, Daguindau N, Le Gouill S, Pica GM, Martin Garcia-Sancho A, López-Guillermo A, Larouche JF, Ando K, Gomes Da Silva M, André M, Zachée P, Sehn LH, Tobinai K, Cartron G, Liu D, Wang J, Xerri L, Salles GA, + collaborators (among others :, Bron D
Jaar : 2018
Journal : N Engl J Med
Volume : 379
Pagina's : 934-947

Mesenchymal stromal cells of the bone marrow and natural killer cells: cell interactions and cross modulation.

Auteurs : Najar M, Fayyad-Kazan M, Meuleman N, Bron D, Fayyad-Kazan H, Lagneaux L
Jaar : 2018
Journal : J Cell Commun Signal
Volume : 12(4)
Pagina's : 673-688

Insights into inflammatory priming of mesenchymal stromal cells: functional biological impacts.

Auteurs : Najar M, Krayem M, Merimi M, Burny A, Meuleman N, Bron D, Raicevic G, Lagneaux L
Jaar : 2018
Journal : Inflamm Res
Volume : 67(6)
Pagina's : 467-477

Immunohematology Mesenchymal Stromal Cell-based Therapy: From Research to Clinic.

Auteurs : Najar M, Krayem M, Meuleman N, Bron D, Hélène B, Lagneaux L
Jaar : 2018
Journal : Appl Immunohistochem Mol Morphol
Volume : 26(3)
Pagina's : e26-e43

Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study.

Auteurs : Luen SJ, Salgado R, Fox S, Savas P, Eng-Wong J, Clark E, Kiermaier A, Swain SM, Baselga J, Michiels S, Loi S
Jaar : 2017
Journal : Lancet Oncol
Volume : 18(1)
Pagina's : 52-62

Reply to M. Lambertini et al.

Auteurs : Demeestere I, Brice P, Peccatori FA, Kentos A, Dupuis J, Zachee P, Casasnovas RO, Van Den Neste E, Dechene J, De Maertelaer V, Bron D, Englert Y
Jaar : 2017
Journal : J Clin Oncol
Volume : 35(7)
Pagina's : 805-6

Low dose clofarabine in combination with a standard remission induction in patients 18-60 years with previously untreated intermediate and bad risk acute myeloid leukemia or high risk myelodysplastic syndrome: combined Phase I/II results of the EORTC

Auteurs : Selleslag D, Suciu S, Meloni G, Muus P, Halkes CJ, Venditti A, Ramadan SM, Pruijt H, Meert L, Vignetti M, Marie JP, Wittnebel S, de Witte T, Amadori S, Willemze R, Baron F
Jaar : 2017
Journal : Haematologica
Volume : 102(2)
Pagina's : e47-51

Improved survival in patients with CALR1 compared to CALR2 mutated primary myelofibrosis: a meta-analysis.

Auteurs : Kourie HR, Ameye L, Paesmans M, Bron D
Jaar : 2017
Journal : Br J Haematol
Volume : 179 (5)
Pagina's : 846-848

Mediastinal Grey Zone Lymphoma: clinico-pathological characteristics and outcomes of 99 patients from the LYSA.

Auteurs : Sarkozy C, Molina T, Ghesquières H, Michallet AS, Dupuis J, Damotte D, Morsschauser F, Parrens M, Martin L, Dartigues P, Stamatoullas A, Hirsch P, Fabiani B, Bouabdallah K, Gomes Da Silva M, Maerevoet M, Laurent C, Coiffier B, Salles G, Traverse-Glehen A
Jaar : 2017
Journal : Haematologica
Volume : 102(1)
Pagina's : 150-9

Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced Malignancies.

Auteurs : Aftimos P, Rolfo C, Rottey S, Offner F, Bron D, Maerevoet M, Soria JC, Moshir M, Dreier T, Van Rompaey L, Michot JM, Silence K, Hultberg A, Gandini D, de Haard H, Ribrag V, Peeters M, Thibault A, Leupin N, Awada A
Jaar : 2017
Journal : Clin Cancer Res
Volume : 23(21)
Pagina's : 6411-6420

Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE).

Auteurs : Loibl S, de la Pena L, Nekljudova V, Zardavas D, Michiels S, Denkert C, Rezai M, Bermejo B, Untch M, Lee SC, Turri S, Urban P, Kümmel S, Steger G, Gombos A, Lux M, Piccart-Gebhart M, Von Minckwitz G, Baselga J, Loi S
Jaar : 2017
Journal : Eur J Cancer
Volume : 85
Pagina's : 133-145